211 related articles for article (PubMed ID: 28958808)
21. Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells.
Yonkers NL; Rodriguez B; Asaad R; Lederman MM; Anthony DD
PLoS One; 2011; 6(9):e23884. PubMed ID: 21912648
[TBL] [Abstract][Full Text] [Related]
22. [Resiquimod (R848) has more stronger immune adjuvantivity than other tested TLR agonists].
Shen Y; Zeng M; Qiu F; Tang H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):591-596. PubMed ID: 28502294
[TBL] [Abstract][Full Text] [Related]
23. Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation.
Gujer C; Sundling C; Seder RA; Karlsson Hedestam GB; Loré K
Immunology; 2011 Nov; 134(3):257-69. PubMed ID: 21977996
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.
Liang H; Russell RS; Yonkers NL; McDonald D; Rodriguez B; Harding CV; Anthony DD
J Virol; 2009 Jun; 83(11):5693-707. PubMed ID: 19297478
[TBL] [Abstract][Full Text] [Related]
25. Combined TLR-3/TLR-8 Signaling in the Presence of α-Type-1 Cytokines Represents a Novel and Potent Dendritic Cell Type-1, Anti-Cancer Maturation Protocol.
Fevžer T; Poženel P; Zajc K; Tešić N; Švajger U
Cells; 2022 Feb; 11(5):. PubMed ID: 35269457
[TBL] [Abstract][Full Text] [Related]
26. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
27. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
28. Formulation of aluminum hydroxide adjuvant with TLR agonists poly(I:C) and CpG enhances the magnitude and avidity of the humoral immune response.
Lu F; Mosley YC; Carmichael B; Brown DD; HogenEsch H
Vaccine; 2019 Mar; 37(14):1945-1953. PubMed ID: 30803844
[TBL] [Abstract][Full Text] [Related]
29. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
30. Variable requirement of dendritic cells for recruitment of NK and T cells to different TLR agonists.
Uchida T; Scumpia PO; Murasko DM; Seki S; Woulfe S; Clare-Salzler MJ; Moldawer LL
J Immunol; 2007 Mar; 178(6):3886-92. PubMed ID: 17339488
[TBL] [Abstract][Full Text] [Related]
31. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
32. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
[TBL] [Abstract][Full Text] [Related]
33. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
Arsenault RJ; Kogut MH; He H
Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
[TBL] [Abstract][Full Text] [Related]
34. Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands-A Role for CCL2.
Gomes AC; Mohsen MO; Mueller JE; Leoratti FMS; Cabral-Miranda G; Bachmann MF
Front Immunol; 2019; 10():1679. PubMed ID: 31428084
[TBL] [Abstract][Full Text] [Related]
35. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
[TBL] [Abstract][Full Text] [Related]
36. CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
Wong KL; Tang LF; Lew FC; Wong HS; Chua YL; MacAry PA; Kemeny DM
J Immunol; 2009 Jul; 183(1):41-50. PubMed ID: 19535645
[TBL] [Abstract][Full Text] [Related]
37. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
38. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
39. TLR-activated dendritic cells enhance the response of aged naive CD4 T cells via an IL-6-dependent mechanism.
Jones SC; Brahmakshatriya V; Huston G; Dibble J; Swain SL
J Immunol; 2010 Dec; 185(11):6783-94. PubMed ID: 20980632
[TBL] [Abstract][Full Text] [Related]
40. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
